• Abortion;
  • human immunodeficiency virus;
  • in vitro fertilization;
  • leukocyte;
  • neonatal alloimmune thrombocytopenia;
  • rhesus hemolytic disease

Problem  Lymphocyte immunotherapy (LIT) is applied in infertility treatment. Moreover, it has been suggested for prevention of rhesus D-hemolytic disease and as a vaccine for reduction of human immunodeficiency virus-1 susceptibility. Although transfusion-related problems have been rarely reported they were a matter of debate. Here we discuss extensive single-center experience with intradermal LIT for implantation failure and recurrent miscarriages.

Method of study  Retrospective 2- to 3-year follow-up of in vitro fertilization couples treated during 1996–2002 (feedback 2848/3041 = 93%), registering 930 deliveries. Prospective survey for acute reactions for 2000–2003 (feedback 2687/3246 = 83%). Review of the literature.

Results  Infections of the patient and transplant rejection later in life are minor residual risks. Post-transfusion purpura was suspected once but not verified. Anaphylaxis or malignancy were not promoted. Fetal/newborn alloimmune disease (severe hemolytic disease, thrombocytopenia, neutropenia) were not observed.

Conclusion  Based on microbiological, immunological, and hematological testing the risks of intradermal LIT are low.